ID   K562/CP
AC   CVCL_AZ73
SY   K-562/CP
DR   BTO; BTO:0005801
DR   Wikidata; Q54899407
RX   PubMed=25356864;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 29-06-23; Version: 14
//
RX   PubMed=25356864; DOI=10.1038/cddis.2014.461;
RA   Nie C., Luo Y., Zhao X., Luo N., Tong A., Liu X., Yuan Z., Wang C.,
RA   Wei Y.;
RT   "Caspase-9 mediates Puma activation in UCN-01-induced apoptosis.";
RL   Cell Death Dis. 5:e1495.1-e1495.13(2014).
//